. Author manuscript; available in PMC: 2016 Feb 12.

Published in final edited form as: Future Virol. 2015;10(8):981–997. doi: 10.2217/fvl.15.64

Table 5.

IL28B polymorphisms and treatment responses (SVR12) in patients receiving new DAAs for HCV-1 infection.

Agent	Study cohort	IL28B genotypes (rs12979860)			Ref.
Agent	Study cohort	CC	CT	TT	Ref.
Simeprevir + PEG- IFN + RBV	264 white (86%), black or African–American (10%)	94%	76%	65%	[80]
Simeprevir + PEG- IFN + RBV	257 white (92%), black or African–American (6%)	96%	80%	58%	[81]
Sofosbuvir + Ledipsavir	865 treatment naive, white (∼85%), black (∼12%)	100%	99.2–100%	9 7.7–10 0 %	[27]
daclatasvir + asunaprevir	645, white (∼70%), black (∼5%), Asian (∼24%)	76–89%	81–88%	86–96%	[82]
Paritaprevir/r, ombitasvir, dasabuvir	380 primarily whites (∼95%)	94–97%	91–96%		[34]

DAA: Direct-acting antiviral; HCV: Hepatitis C virus; PEG-IFN: Pegylated interferon; RBV: Ribavirin; r: Ritonavir.